An official website of the United States government
Home
Name
Lutrin
Alternate Names
Lutetium texaphyrin
Motexafin lutetium
Lutetium Lu77
Lutathera
Abbreviations
LU-177
Category
Radiation
Subcategory
NSC Number
695239
Primary Site
Histology
None
Remarks
IMPORTANT INSTRUCTIONS: See STORE and SEER program manuals for coding instructions.
April 23, 2024 FDA approved lutetium Lu 177 dotatate (Lutathera) for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Lutetium Lu 177 dotatate received approval for this indication for adults in 2018.
Feb 2, 2018 FDA has approved lutetium LU 177 dotatate, a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroen-teropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Lutathera is: A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 with potential antineoplastic activities.
April 23, 2024 FDA approved lutetium Lu 177 dotatate (Lutathera) for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Lutetium Lu 177 dotatate received approval for this indication for adults in 2018.
Feb 2, 2018 FDA has approved lutetium LU 177 dotatate, a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroen-teropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Lutathera is: A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 with potential antineoplastic activities.
Coding
This drug should be coded
